Longitudinal study of depot medroxyprogesterone acetate (Depo-Provera®) effects on bone health in adolescents

study design, population characteristics and baseline bone mineral density

Christine C. Johnson, Ronald T. Burkman, Melanie A. Gold, Robert T. Brown, Zeev Harel, Ann Bruner, Margaret Stager, Laura K. Bachrach, S. Paige Hertweck, Anita L. Nelson, Dorothy A. Nelson, Susan M. Coupey, Alison McLeod, Henry G. Bone

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Background: This analysis was conducted to assess the baseline data and design methodology within an observational longitudinal comparison of use vs. nonuse of the injectable (intramuscular) contraceptive depot medroxyprogesterone acetate (DMPA-IM) and its effect on bone mass in adolescent women. Study Design: A prospective, observational, open-label, unmatched-cohort, safety study in females aged 11-18 years. Participants either self-selected DMPA-IM (Depo-Provera®) 150 mg to be administered every 12 weeks for up to 240 weeks with a 120-week post-treatment follow-up or were nonusers (users of nonhormonal contraception or sexually abstinent) who were to be followed up for up to 360 weeks. As each participant entered the study, bone mineral density (BMD) was measured by dual-energy X-ray absorptiometry at the lumbar spine, hip and femoral neck regions, along with total body bone mineral content; serum and urine specimens were obtained for assay of bone metabolism markers and participants' histories of parity and tobacco and alcohol use were obtained. Results: A total of 389 participants were enrolled: 169 elected to begin DMPA-IM; 26 chose nonhormonal methods and 194 were abstinent. The baseline characteristics indicated significant disparities between DMPA-IM users and nonusers: compared with the nonusers, DMPA-IM users had more advanced chronologic and gynecologic ages, were more likely to have smoked, been pregnant and included more blacks. These factors would likely influence bone accretion rates independent of DMPA-IM exposure. Comparison of participant BMDs with standard reference data revealed that the study cohorts did not match reference populations closely enough to make a direct between-cohort comparative analysis feasible. Conclusions: The baseline differences in cohort characteristics preclude a meaningful comparison of mean BMD changes over time between DMPA-IM users and nonusers cohorts, and comparisons of changes in Z-scores between cohorts were also not appropriate. Therefore, within-participant BMD decreases from baseline were established as safety thresholds, and the proportion of individuals crossing those thresholds on a persistent or progressive basis was identified as the revised primary end point.

Original languageEnglish (US)
Pages (from-to)239-248
Number of pages10
JournalContraception
Volume77
Issue number4
DOIs
StatePublished - Apr 2008

Fingerprint

Medroxyprogesterone Acetate
Population Characteristics
Bone Density
Longitudinal Studies
Bone and Bones
Cohort Studies
Safety
Femur Neck
Photon Absorptiometry
Tobacco Use
Contraceptive Agents
Parity
Adolescent Health
N,N-dimethyl-4-anisidine
Contraception
Hip
Spine
Alcohols
Urine
Injections

Keywords

  • Adolescent
  • Bone density
  • Contraceptive agents
  • Depot medroxyprogesterone acetate

ASJC Scopus subject areas

  • Medicine(all)
  • Obstetrics and Gynecology

Cite this

Longitudinal study of depot medroxyprogesterone acetate (Depo-Provera®) effects on bone health in adolescents : study design, population characteristics and baseline bone mineral density. / Johnson, Christine C.; Burkman, Ronald T.; Gold, Melanie A.; Brown, Robert T.; Harel, Zeev; Bruner, Ann; Stager, Margaret; Bachrach, Laura K.; Hertweck, S. Paige; Nelson, Anita L.; Nelson, Dorothy A.; Coupey, Susan M.; McLeod, Alison; Bone, Henry G.

In: Contraception, Vol. 77, No. 4, 04.2008, p. 239-248.

Research output: Contribution to journalArticle

Johnson, CC, Burkman, RT, Gold, MA, Brown, RT, Harel, Z, Bruner, A, Stager, M, Bachrach, LK, Hertweck, SP, Nelson, AL, Nelson, DA, Coupey, SM, McLeod, A & Bone, HG 2008, 'Longitudinal study of depot medroxyprogesterone acetate (Depo-Provera®) effects on bone health in adolescents: study design, population characteristics and baseline bone mineral density', Contraception, vol. 77, no. 4, pp. 239-248. https://doi.org/10.1016/j.contraception.2007.11.002
Johnson, Christine C. ; Burkman, Ronald T. ; Gold, Melanie A. ; Brown, Robert T. ; Harel, Zeev ; Bruner, Ann ; Stager, Margaret ; Bachrach, Laura K. ; Hertweck, S. Paige ; Nelson, Anita L. ; Nelson, Dorothy A. ; Coupey, Susan M. ; McLeod, Alison ; Bone, Henry G. / Longitudinal study of depot medroxyprogesterone acetate (Depo-Provera®) effects on bone health in adolescents : study design, population characteristics and baseline bone mineral density. In: Contraception. 2008 ; Vol. 77, No. 4. pp. 239-248.
@article{8467f03242554f3eaf9c25433cdf03e9,
title = "Longitudinal study of depot medroxyprogesterone acetate (Depo-Provera{\circledR}) effects on bone health in adolescents: study design, population characteristics and baseline bone mineral density",
abstract = "Background: This analysis was conducted to assess the baseline data and design methodology within an observational longitudinal comparison of use vs. nonuse of the injectable (intramuscular) contraceptive depot medroxyprogesterone acetate (DMPA-IM) and its effect on bone mass in adolescent women. Study Design: A prospective, observational, open-label, unmatched-cohort, safety study in females aged 11-18 years. Participants either self-selected DMPA-IM (Depo-Provera{\circledR}) 150 mg to be administered every 12 weeks for up to 240 weeks with a 120-week post-treatment follow-up or were nonusers (users of nonhormonal contraception or sexually abstinent) who were to be followed up for up to 360 weeks. As each participant entered the study, bone mineral density (BMD) was measured by dual-energy X-ray absorptiometry at the lumbar spine, hip and femoral neck regions, along with total body bone mineral content; serum and urine specimens were obtained for assay of bone metabolism markers and participants' histories of parity and tobacco and alcohol use were obtained. Results: A total of 389 participants were enrolled: 169 elected to begin DMPA-IM; 26 chose nonhormonal methods and 194 were abstinent. The baseline characteristics indicated significant disparities between DMPA-IM users and nonusers: compared with the nonusers, DMPA-IM users had more advanced chronologic and gynecologic ages, were more likely to have smoked, been pregnant and included more blacks. These factors would likely influence bone accretion rates independent of DMPA-IM exposure. Comparison of participant BMDs with standard reference data revealed that the study cohorts did not match reference populations closely enough to make a direct between-cohort comparative analysis feasible. Conclusions: The baseline differences in cohort characteristics preclude a meaningful comparison of mean BMD changes over time between DMPA-IM users and nonusers cohorts, and comparisons of changes in Z-scores between cohorts were also not appropriate. Therefore, within-participant BMD decreases from baseline were established as safety thresholds, and the proportion of individuals crossing those thresholds on a persistent or progressive basis was identified as the revised primary end point.",
keywords = "Adolescent, Bone density, Contraceptive agents, Depot medroxyprogesterone acetate",
author = "Johnson, {Christine C.} and Burkman, {Ronald T.} and Gold, {Melanie A.} and Brown, {Robert T.} and Zeev Harel and Ann Bruner and Margaret Stager and Bachrach, {Laura K.} and Hertweck, {S. Paige} and Nelson, {Anita L.} and Nelson, {Dorothy A.} and Coupey, {Susan M.} and Alison McLeod and Bone, {Henry G.}",
year = "2008",
month = "4",
doi = "10.1016/j.contraception.2007.11.002",
language = "English (US)",
volume = "77",
pages = "239--248",
journal = "Contraception",
issn = "0010-7824",
publisher = "Elsevier USA",
number = "4",

}

TY - JOUR

T1 - Longitudinal study of depot medroxyprogesterone acetate (Depo-Provera®) effects on bone health in adolescents

T2 - study design, population characteristics and baseline bone mineral density

AU - Johnson, Christine C.

AU - Burkman, Ronald T.

AU - Gold, Melanie A.

AU - Brown, Robert T.

AU - Harel, Zeev

AU - Bruner, Ann

AU - Stager, Margaret

AU - Bachrach, Laura K.

AU - Hertweck, S. Paige

AU - Nelson, Anita L.

AU - Nelson, Dorothy A.

AU - Coupey, Susan M.

AU - McLeod, Alison

AU - Bone, Henry G.

PY - 2008/4

Y1 - 2008/4

N2 - Background: This analysis was conducted to assess the baseline data and design methodology within an observational longitudinal comparison of use vs. nonuse of the injectable (intramuscular) contraceptive depot medroxyprogesterone acetate (DMPA-IM) and its effect on bone mass in adolescent women. Study Design: A prospective, observational, open-label, unmatched-cohort, safety study in females aged 11-18 years. Participants either self-selected DMPA-IM (Depo-Provera®) 150 mg to be administered every 12 weeks for up to 240 weeks with a 120-week post-treatment follow-up or were nonusers (users of nonhormonal contraception or sexually abstinent) who were to be followed up for up to 360 weeks. As each participant entered the study, bone mineral density (BMD) was measured by dual-energy X-ray absorptiometry at the lumbar spine, hip and femoral neck regions, along with total body bone mineral content; serum and urine specimens were obtained for assay of bone metabolism markers and participants' histories of parity and tobacco and alcohol use were obtained. Results: A total of 389 participants were enrolled: 169 elected to begin DMPA-IM; 26 chose nonhormonal methods and 194 were abstinent. The baseline characteristics indicated significant disparities between DMPA-IM users and nonusers: compared with the nonusers, DMPA-IM users had more advanced chronologic and gynecologic ages, were more likely to have smoked, been pregnant and included more blacks. These factors would likely influence bone accretion rates independent of DMPA-IM exposure. Comparison of participant BMDs with standard reference data revealed that the study cohorts did not match reference populations closely enough to make a direct between-cohort comparative analysis feasible. Conclusions: The baseline differences in cohort characteristics preclude a meaningful comparison of mean BMD changes over time between DMPA-IM users and nonusers cohorts, and comparisons of changes in Z-scores between cohorts were also not appropriate. Therefore, within-participant BMD decreases from baseline were established as safety thresholds, and the proportion of individuals crossing those thresholds on a persistent or progressive basis was identified as the revised primary end point.

AB - Background: This analysis was conducted to assess the baseline data and design methodology within an observational longitudinal comparison of use vs. nonuse of the injectable (intramuscular) contraceptive depot medroxyprogesterone acetate (DMPA-IM) and its effect on bone mass in adolescent women. Study Design: A prospective, observational, open-label, unmatched-cohort, safety study in females aged 11-18 years. Participants either self-selected DMPA-IM (Depo-Provera®) 150 mg to be administered every 12 weeks for up to 240 weeks with a 120-week post-treatment follow-up or were nonusers (users of nonhormonal contraception or sexually abstinent) who were to be followed up for up to 360 weeks. As each participant entered the study, bone mineral density (BMD) was measured by dual-energy X-ray absorptiometry at the lumbar spine, hip and femoral neck regions, along with total body bone mineral content; serum and urine specimens were obtained for assay of bone metabolism markers and participants' histories of parity and tobacco and alcohol use were obtained. Results: A total of 389 participants were enrolled: 169 elected to begin DMPA-IM; 26 chose nonhormonal methods and 194 were abstinent. The baseline characteristics indicated significant disparities between DMPA-IM users and nonusers: compared with the nonusers, DMPA-IM users had more advanced chronologic and gynecologic ages, were more likely to have smoked, been pregnant and included more blacks. These factors would likely influence bone accretion rates independent of DMPA-IM exposure. Comparison of participant BMDs with standard reference data revealed that the study cohorts did not match reference populations closely enough to make a direct between-cohort comparative analysis feasible. Conclusions: The baseline differences in cohort characteristics preclude a meaningful comparison of mean BMD changes over time between DMPA-IM users and nonusers cohorts, and comparisons of changes in Z-scores between cohorts were also not appropriate. Therefore, within-participant BMD decreases from baseline were established as safety thresholds, and the proportion of individuals crossing those thresholds on a persistent or progressive basis was identified as the revised primary end point.

KW - Adolescent

KW - Bone density

KW - Contraceptive agents

KW - Depot medroxyprogesterone acetate

UR - http://www.scopus.com/inward/record.url?scp=40649121963&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=40649121963&partnerID=8YFLogxK

U2 - 10.1016/j.contraception.2007.11.002

DO - 10.1016/j.contraception.2007.11.002

M3 - Article

VL - 77

SP - 239

EP - 248

JO - Contraception

JF - Contraception

SN - 0010-7824

IS - 4

ER -